|
IGHV3OR16-7
|
Congenital chromosomal disease
|
0.100 |
GeneticVariation |
BEFREE |
A strong overall correlation existed between the presence of different chromosome abnormalities and a number of prognostic factors including immunoglobulin heavy chain variable region mutation status (P = 0.011), time to treatment (P = 0.025) and lymphocyte doubling time (P = 0.034).
|
15686453 |
2005 |
|
IGHV3OR16-7
|
Congenital chromosomal disease
|
0.100 |
GeneticVariation |
BEFREE |
The expression of ZAP-70 mRNA was significantly associated with Binet stage (P < 0.001), lactate dehydrogenase (P = 0.003), ZAP-70 protein (P = 0.018), IGHV mutational status (P = 0.038), and cytogenetic abnormality of del(17p13) or del(11q22.3) (P = 0.037) in CLL patients.
|
22362302 |
2012 |
|
IGHV3OR16-7
|
Congenital chromosomal disease
|
0.100 |
GeneticVariation |
BEFREE |
IGHV-mutated cases were significantly more frequent among cMBLs (P = 0.005), whereas the distribution of CD38 and ZAP-70 positive cases, of patients with NOTCH1 and SF3B1 mutations or exhibiting the major CLL cytogenetic abnormalities, was similar in the two groups.
|
24036852 |
2013 |
|
IGHV3OR16-7
|
Congenital chromosomal disease
|
0.100 |
GeneticVariation |
BEFREE |
The data on cytogenetic aberrations (11q22, 13q14, trisomy 12) and IGHV mutation status were also considered in PFS analyses.
|
31054420 |
2019 |
|
IGHV3OR16-7
|
Congenital chromosomal disease
|
0.100 |
GeneticVariation |
BEFREE |
We evaluated its relevance as independent prognosticator for overall survival and time to treatment (TTT) in a series of 303 (232 for TTT) CLLs, in comparison with other biologic or clinical prognosticators (CD38, ZAP-70, immunoglobulin variable heavy chain (IGHV) gene status, cytogenetic abnormalities, soluble CD23, beta2-microglobulin, Rai staging).
|
17959854 |
2008 |
|
IGHV3OR16-7
|
Congenital chromosomal disease
|
0.100 |
GeneticVariation |
BEFREE |
Prognostic factors such as chromosome abnormalities (trisomy 12, 11q deletions and 17p deletions), β2 microglobulin, thymidine kinase, CD38 and ZAP-70 expression, IGHV mutation status, and mutations in genes such as NOTCH1, MYD88, SF3B1, and ATM are also predictors of prognosis.
|
27742074 |
2016 |
|
IGHV3OR16-7
|
Congenital chromosomal disease
|
0.100 |
GeneticVariation |
BEFREE |
A significantly lower expression of LAIR1 was observed in patients with Binet stage B or C disease (P=0.023), and in the presence of high-risk cytogenetic abnormalities (P=0.048) or unmutated immunoglobulin heavy chain variable region genes (P<0.0001).
|
24415628 |
2014 |
|
IGHV3OR16-7
|
Congenital chromosomal disease
|
0.100 |
GeneticVariation |
BEFREE |
On pooled multivariable analysis of patients in both cohorts adjusting for age, sex, Rai stage, CD38 status, ZAP-70 status, immunoglobulin heavy chain variable (IGHV) gene mutation status, CD49d status, and cytogenetic abnormalities assessed by interphase fluorescent in situ hybridization testing, 25(OH)D insufficiency remained an independent predictor of TTT (HR = 1.47; P = .008), although the association with OS was not significant (HR = 1.47; P = .07).
|
21048153 |
2011 |
|
IGHV3OR16-7
|
Congenital chromosomal disease
|
0.100 |
GeneticVariation |
BEFREE |
In the overall patient population, prognostic parameters such as IGHV gene mutational status (P < .0001), CD38 expression (P < .0001), 70-kDa zeta-associated protein (ZAP-70) expression (P < .0001), and cytogenetic abnormalities (P = .01) predicted for TTFT on univariate analysis.
|
25445470 |
2015 |
|
IGHV3OR16-7
|
Congenital chromosomal disease
|
0.100 |
GeneticVariation |
BEFREE |
Clinical features and molecular/biologic factors such as ZAP-70, immunoglobulin heavy chain (IGHV) gene mutation status, and cytogenetic abnormalities on fluorescent in situ hybridization (FISH) have been found to be robust predictors of treatment-free survival and overall survival among newly diagnosed patients.
|
20008228 |
2009 |
|
IGHV3OR16-7
|
Congenital chromosomal disease
|
0.100 |
GeneticVariation |
BEFREE |
Differences related to the expression of 25 miRNAs were found to be independent from IGHV mutation status or cytogenetic aberrations.
|
24916701 |
2014 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Overall, the methylation pattern correlated with the major biological (ZAP-70 and CD38), and molecular (IGHV mutation) markers, distinguishing CLL cases according to IGHV mutational status.
|
24347044 |
2014 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
The RPPA investigation and its validation, identified 3 series of proteins: 1) molecules whose expression levels reached statistically significant differences in CLL vs. healthy controls (HSP70, Smac/DIABLO, cleaved PARP, and cleaved caspase-6); 2) proteins with a positive trend of difference in CLL vs. healthy controls (HS1, γ-tubulin, PKC α/β-II Thr-638/641, p38 MAPK Thr-180/Tyr-182, NF-κB Ser-536, Bcl2 Ser-70 and Src Tyr-527); and 3) molecules differentially expressed in patients with IGHV mutations vs. those without mutations (ZAP70, PKC-ζλ, Thr-410/403, and CD45).
|
27312846 |
2016 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
These data suggest that del(13q) conveys an indolent course only in patients with IGHV-mutated CLL.
|
21851216 |
2011 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Chromosomal aberrations, IGHV and TP53 mutation status are well-established and essential to discriminate between a more indolent course of disease and a high-risk CLL, which requires an alternative treatment regimen.
|
26890126 |
2016 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
We retrospectively analyzed 463 patients with CLL with available immunoglobulin heavy-chain variable (IGHV) gene status and B-cell receptor (BCR) configuration [heavy-chain complementary-determining region 3 (HCDR3)], of whom thirty-six developed ITP, according to previously defined criteria.
|
22322667 |
2012 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Mutations in known CLL drivers are seen in only 33% of this cohort, and associated with normal cytogenetics and unmutated IGHV.
|
26638776 |
2015 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
The aim of this work was to characterize hTERT splice variants in CLL in relation to disease activity, clinical stage, immunoglobulin heavy chain variable (IGHV) genes mutational status, and TL.
|
23548418 |
2013 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
A marked increase of DEK mRNA expression was observed in the CLL patients with unmutated immunoglobulin heavy chain variable (IGHV) gene (p = 0.025), CD38-positive (p = 0.047), del(17p13) (p = 0.006).
|
23052131 |
2012 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Identical IGHV-D-J gene rearrangement may precede the clinical onset of chronic lymphocytic leukemia by several years.
|
20872553 |
2010 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
The immunoglobulin heavy chain variable (IGHV) gene mutational status represents a major prognostic marker in chronic lymphocytic leukemia (CLL).
|
23450508 |
2013 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Moreover, discordant ISO(+)TNK(-) cases had a IgV(H) gene mutation profile similar to that of concordantly positive cases and different from ZAP-70 concordantly negative B-CLL.
|
16906587 |
2006 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
The expression of several genes correlates closely with the IGHV mutational status and could be used to assess prognosis in CLL.
|
27185377 |
2017 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
These agents lead to improved outcomes in CLL, even among patients with high-risk features, such as del17p13 or TP53 mutation and unmutated immunoglobulin heavy chain (IGHV) genes.
|
30283014 |
2018 |
|
IGHV3OR16-7
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
CLL cases can be divided in two subgroups with different clinical course based on the mutational status of the immunoglobulin heavy variable (IGHV) genes: mutated CLL (M-CLL) and unmutated CLL (U-CLL).
|
31108207 |
2019 |